Long-term observation of the frequency of secondary colorectal cancer and other malignancies in tyrosine kinase inhibitor treated chronic myeloid leukemia patients and controls.

chronic myeloid leukemia colorectal cancer secondary malignancy

Journal

EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 07 04 2022
revised: 22 05 2022
accepted: 24 05 2022
entrez: 2 9 2022
pubmed: 3 9 2022
medline: 3 9 2022
Statut: epublish

Résumé

In this analysis, we examined the risk of secondary malignancies for tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML) patients. We also collected data on specific risk factors for colorectal cancer. Ninety-one patients with CML and 76 controls were included and in total 4 (4.4%) secondary malignancies were found in patients and 8 (10.5%) in controls. The risk for secondary malignancies was not significantly elevated for CML patients (

Identifiants

pubmed: 36051062
doi: 10.1002/jha2.502
pii: JHA2502
pmc: PMC9422034
doi:

Types de publication

Journal Article

Langues

eng

Pagination

949-953

Informations de copyright

© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Références

Leukemia. 2005 Sep;19(9):1689-92
pubmed: 16015386
Best Pract Res Clin Haematol. 2009 Sep;22(3):295-302
pubmed: 19959081
Cancer. 2012 Jun 15;118(12):3123-7
pubmed: 22294282
Br J Haematol. 2015 Jun;169(5):683-8
pubmed: 25817799
N Engl J Med. 2017 Mar 9;376(10):917-927
pubmed: 28273028
PeerJ. 2018 Feb 12;6:e4342
pubmed: 29456888
Lancet Oncol. 2016 May;17(5):612-21
pubmed: 27083332
Leukemia. 2015 May;29(5):1123-32
pubmed: 25676422
Blood. 2011 Oct 20;118(16):4353-8
pubmed: 21846902
J Clin Oncol. 2011 Apr 20;29(12):1634-42
pubmed: 21422420
Blood. 2011 Oct 27;118(17):4567-76
pubmed: 21865346
Leukemia. 2016 May;30(5):1044-54
pubmed: 26837842
Leukemia. 2016 Jun;30(6):1255-62
pubmed: 26859076

Auteurs

Nina Winkelmann (N)

Department of Hematology, Oncology, and Cancer Immunology, Campus Charité Mitte Charité-Universitätsmedizin Berlin Berlin Germany.

Michaela Schwarz (M)

Department of Hematology, Oncology, and Cancer Immunology, Campus Virchow-Klinikum Charité- Universitätsmedizin Berlin Berlin Germany.

Bert Hildebrandt (B)

Department of Hematology, Oncology, and Cancer Immunology, Campus Charité Mitte Charité-Universitätsmedizin Berlin Berlin Germany.

Oliver Henke (O)

Department of Hematology, Oncology, and Cancer Immunology, Campus Charité Mitte Charité-Universitätsmedizin Berlin Berlin Germany.

Lars Bullinger (L)

Department of Hematology, Oncology, and Cancer Immunology, Campus Virchow-Klinikum Charité- Universitätsmedizin Berlin Berlin Germany.

Il-Kang Na (IK)

Department of Hematology, Oncology, and Cancer Immunology, Campus Virchow-Klinikum Charité- Universitätsmedizin Berlin Berlin Germany.

Sebastian Stintzing (S)

Department of Hematology, Oncology, and Cancer Immunology, Campus Charité Mitte Charité-Universitätsmedizin Berlin Berlin Germany.

Philipp le Coutre (P)

Department of Hematology, Oncology, and Cancer Immunology, Campus Charité Mitte Charité-Universitätsmedizin Berlin Berlin Germany.

Classifications MeSH